Kinnate Biopharma
Kinnate Biopharma Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s lead programs include candidates in development for cancers that are driven by specific oncogenic alterations in kinase genes including BRAF Class II and Class III, NRAS, and FGFR2 and FGFR3. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products that are designed to address significant unmet need.